PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents yoy growth below half of AVXL's 90.54%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
-100.00%
Both AVXL and the company show zero Short-Term Investments Growth.
3.51%
Below half of AVXL's 90.54%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
Below half of AVXL's 92.37%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
11.32%
Below half AVXL's -28.42%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-18.41%
0.5-0.75x AVXL's -28.42%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Below half of AVXL's 92.34%. Michael Burry sees a potential red flag for stagnation or capital shortage.
65.90%
50-75% of AVXL's 104.56%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Exceeding 1.5x AVXL's 39.81%. Michael Burry suspects ballooning short-term obligations vs. competitor.
114.06%
50-75% of AVXL's 165.67%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
50-75% of AVXL's 161.27%. Bruce Berkowitz notes a lower yoy liability increase.
5.13%
Less than half of AVXL's -66.47%. David Dodd sees fewer share issuances vs. competitor.
-6.19%
1.25-1.5x AVXL's -4.33%. Bruce Berkowitz notes stronger reinvestment strategy.
-12.13%
50-75% of AVXL's -16.45%. Bruce Berkowitz notes relatively lower AOCI expansions.
-100.00%
Similar yoy changes to AVXL's -100.00%. Walter Schloss finds parallel equity item fluctuations.
-4.02%
Below half AVXL's 82.35%. Michael Burry sees potential underperformance in building shareholder capital.
6.14%
Below half AVXL's 92.34%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AVXL and the company show zero Total Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Less than half of AVXL's -92.04%. David Dodd sees better deleveraging or stronger cash buildup than competitor.